Bulk Manufacturer of Controlled Substances Application: Organix Chemistry Solutions, LLC
Published Date: 11/26/2025
Notice
Summary
Organix Chemistry Solutions, LLC wants to become a big-time maker of some powerful controlled substances like LSD and marijuana. If you have thoughts or concerns, you’ve got until January 26, 2026, to speak up or ask for a hearing. This move could shake up who’s allowed to produce these drugs, so keep an eye on the deadline and get involved if you want!
Analyzed Economic Effects
3 provisions identified: 1 benefits, 0 costs, 2 mixed.
New bulk manufacturer application filed
Organix Chemistry Solutions, LLC applied on October 20, 2025 to be registered as a bulk manufacturer of many controlled substances, including lysergic acid diethylamide (LSD, code 7315), marihuana (code 7360), psilocybin (code 7437), heroin (code 9200), and morphine (code 9300). The company says it plans to synthesize the listed substances for distribution to its customers.
Synthetic marijuana/THC manufacturing only
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Organix Chemistry Solutions, LLC plans to bulk manufacture these drugs as synthetic. The registration would not authorize any other activities for those drug codes.
Comment and hearing deadline: Jan 26, 2026
Registered bulk manufacturers of the affected classes, and applicants, may submit electronic comments or objections on or before January 26, 2026, and may file a written request for a hearing by that same date. Comments must be submitted electronically through https://www.regulations.gov.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-22843, Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027
The DEA is setting limits on how much of certain controlled drugs and chemicals can be made in 2027. This affects drug makers and anyone involved in producing or handling these substances. They’re asking for public comments by December 10, 2026, before finalizing the amounts, which helps keep drug supply safe and balanced.
2026-22842, Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sale) Pursuant to 21 U.S.C. 826(h)
The DEA is boosting the 2026 production limits for four important medicines: d,l-amphetamine, d-amphetamine (for sale), hydromorphone, and methylphenidate (for sale). This change helps fix shortages and keeps medicines flowing smoothly. The new quotas take effect right away on November 10, 2026, so manufacturers can ramp up production without delay.
Previous / Next Documents
Previous: 2025-21185, Bulk Manufacturer of Controlled Substances Application: Siegfried Grafton, Inc.
Siegfried Grafton, Inc. wants to become a big-time maker of some powerful controlled substances, including things like LSD and marijuana extracts. People already registered or interested can share their thoughts or ask for a hearing by January 26, 2026. This move could shake up how these substances are produced and tracked, with no direct cost changes announced yet.
Next: 2025-21187, Bulk Manufacturer of Controlled Substances Application: Irvine Labs Inc.
Irvine Labs Inc. wants to make large amounts of some powerful, tightly controlled drugs like psilocybin and LSD for research. People and companies involved with these drugs can share their thoughts or ask for a hearing by January 26, 2026. This move could boost scientific studies but also means careful government oversight and no quick cash changes for now.